Abstract
Many young women with breast cancer are interested in having a biologic child in the future. However, adjuvant chemotherapy can cause ovarian toxicity and fertility naturally declines due to ovarian aging that occurs during the recommended five years of treatment with adjuvant hormonal therapy. Decisions about fertility after breast cancer are further complicated by concerns about the safety of fertility preservation and subsequent pregnancy after breast cancer, despite limited available data for safety. At the present time, the most reliable fertility preservation method for breast cancer patients is embryo cryopreservation prior to treatment, although alternative options exist. In an effort to allow women to pursue fertility preservation if warranted and avoid excessive treatment delay, it is important to consider fertility concerns early in the care of young women with breast cancer.
I am a 35 year old woman whose boyfriend found a mass in my breast two months ago. A biopsy showed it was breast cancer, and I was ultimately recommended to undergo chemotherapy and tamoxifen in addition to surgery. I told them I would very much like to be able to have children in the future, so my oncologist said I should consider embryo cryopreservation, as my likelihood of being able to conceive naturally after chemotherapy and at age 40, when the tamoxifen was finished, would not be high. However, she acknowledged that no one is sure whether ovarian stimulation prior to treatment, especially when my cancer was hormone sensitive, is safe. I met with a reproductive endocrinologist later that week, and we went over the pros and cons of fertility preservation options. My boyfriend I discussed it and we decided to move forward with embryo cryopreservation. Because my period had recently finished, I started ovarian stimulation quickly and had eggs harvested, fertilized with my boyfriend’s sperm, and frozen less than two weeks later. I started chemotherapy the next day. While I realize there is uncertainty about the safety of pregnancy after breast cancer, knowing that I have taken steps to preserve my fertility is very reassuring to me as I begin my treatment.
Diana, Breast Cancer Survivor
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Oktay K et al (2010) Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 28(2):240–244
Adams E et al (2011) The experiences, needs and concerns of younger women with breast cancer: a meta-ethnography. Psychooncology 20(8):851–861
Hickey M et al (2009) Breast cancer in young women and its impact on reproductive function. Hum Reprod Update 15(3):323–339
Partridge AH et al (2004) Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 22(20):4174–4183
Ruddy K et al (2011) Menopausal symptoms and fertility concerns in premenopausal breast cancer survivors. Menopause 18:105–108
Dow KH (1994) Having children after breast cancer. Cancer Pract 2(6):407–413
Thewes B et al (2005) Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol 23(22):5155–5165
Duffy CM, Allen SM, Clark MA (2005) Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. J Clin Oncol 23(4):766–773
Peate M et al (2009) The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review. Breast Cancer Res Treat 116(2):215–223
Peate M et al (2011) Development and pilot testing of a fertility decision aid for young women diagnosed with early breast cancer. Breast J 17(1):112–114
Oktay K, Buyuk E (2004) Fertility preservation in women undergoing cancer treatment. Lancet 363(9423):1830
Oktay K et al (2010) In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. Reprod Biomed Online 20(5):634–638
Oktay K et al (2005) Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 23(19):4347–4353
Azim AA, Costantini-Ferrando M, Oktay K (2008) Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 26(16):2630–2635
Huang JY et al (2010) Retrieval of immature oocytes from unstimulated ovaries followed by in vitro maturation and vitrification: A novel strategy of fertility preservation for breast cancer patients. Am J Surg 200(1):177–183
Hulvat MC, Jeruss JS (2009) Maintaining fertility in young women with breast cancer. Curr Treat Options Oncol 10(5–6):308–317
Porcu E et al (2008) Human oocyte cryopreservation in infertility and oncology. Curr Opin Endocrinol Diab Obes 15(6):529–535
Sanchez-Serrano M et al (2010) Twins born after transplantation of ovarian cortical tissue and oocyte vitrification. Fertil Steril 93(1):268 e11–e13
Partridge AH, Ruddy KJ (2007) Fertility and adjuvant treatment in young women with breast cancer. Breast 2(16 Suppl):S175–S181
Madrigrano A, Westphal L, Wapnir I (2007) Egg retrieval with cryopreservation does not delay breast cancer treatment. Am J Surg 194(4):477–481
Giuseppe L et al (2007) Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 12(2):141–147
Badawy A et al (2009) Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91(3):694–697
Recchia F et al (2006) Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 106(3):514–523
Urruticoechea A et al (2008) Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat 110(3):411–416
Blumenfeld Z, Eckman A (2005) Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 34:40–43
Sverrisdottir A et al (2009) Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 117(3):561–567
Ismail-Khan R et al. (2008) Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: a randomized trial using the GnRH agonist (triptorelin) during chemotherapy. In American Society of clinical oncology annual meeting, Chicago, IL
Gerber B et al (2009) ZORO: a prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37). In 2009 ASCO annual meeting
Southwest Oncology Group: The Group Newsletter (2008) [cited; Volume 22, No. 1: [Available from: http://www.swog.org/Visitors/Download/Newsletters/Newsletter022008.pdf
Partridge A et al (2007) Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer 43(11):1646–1653
Fornier MN et al (2005) Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 104(8):1575–1579
Koyama H et al (1977) Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39(4):1403–1409
Minton SE, Munster PN (2002) Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 9(6):466–472
Parulekar WR et al (2005) Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study–NCIC CTG MA.5.. J Clin Oncol 23(25):6002–6008
Ruddy KJ, Partridge AH (2009) Fertility. In: Castiglione M, Piccart MJ (eds) Adjuvant therapy for breast cancer. Springer, The Netherlands, pp 367–385
Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14(5):1718–1729
Goldhirsch A, Gelber RD, Castiglione M (1990) The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol 1(3):183–188
Petrek JA et al (2006) Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24(7):1045–1051
Abusief ME et al (2010) The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 116(4):791–798
Sukumvanich P et al (2010) Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 116(13):3102–3111
Tham YL et al (2007) The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 30(2):126–132
Najafi S et al (2011) Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea. Menopause 18(2):208–212
Anderson RA et al (2006) The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21(10):2583–2592
Zhou WB et al (2010) Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients. BMC Cancer 10:281
La Marca A et al (2010) Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 16(2):113–130
Lutchman Singh K et al (2007) Predictors of ovarian reserve in young women with breast cancer. Br J Cancer 96(12):1808–1816
Su HI et al (2010) Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 116(3):592–599
Anders C et al (2008) A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 26(3):286–295
Partridge AH et al (2010) Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 94(2):634–644
Yu B et al (2010) Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 116(9):2099–2105
Fox KR, Scialla J, Moore H (2003) Preventing chemotherapy-related amenorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer [abstract 50]. Proc Am Soc Clin Onc 22:13
Ives A et al (2007) Pregnancy after breast cancer: population based study. BMJ 334(7586):194
Hawkins MM (1994) Pregnancy outcome and offspring after childhood cancer. BMJ 309(6961):1034
Blakely LJ et al (2004) Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 100(3):465–469
Velentgas P et al (1999) Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer 85(11):2424–2432
Mulvihill JJ et al (1987) Pregnancy outcome in cancer patients. Experience in a large cooperative group. Cancer 60(5):1143–1150
Dow KH, Harris JR, Roy C (1994) Pregnancy after breast-conserving surgery and radiation therapy for breast cancer. J Natl Cancer Inst Monogr 16:131–137
Sankila R, Heinavaara S, Hakulinen T (1994) Survival of breast cancer patients after subsequent term pregnancy: “healthy mother effect”. Am J Obstet Gynecol 170(3):818–823
Kroman N et al (1997) Time since childbirth and prognosis in primary breast cancer: population based study. BMJ 315(7112):851–855
von Schoultz E et al (1995) Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol 13(2):430–434
Kranick JA et al (2010) Is pregnancy after breast cancer safe? Breast J 16(4):404–411
Rippy EE, Karat IF, Kissin MW (2009) Pregnancy after breast cancer: the importance of active counselling and planning. Breast 18(6):345–350
Swain SM et al (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362(22):2053–2065
Ellis M (2010) Taxane-based chemotherapy for node-positive breast cancer–take-home lessons. N Engl J Med 362(22):2122–2124
Puhalla S, Brufsky A, Davidson N (2009) Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast 18(Suppl 3):S122–S1230
Lee SJ et al (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24(18):2917–2931
Goodwin PJ et al (1999) Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17(8):2365–2370
Burstein HJ, Winer EP (2000) Primary care for survivors of breast cancer. N Engl J Med 343(15):1086–1094
Martin M et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22):2302–2313
Han HS et al (2008) Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat 115(2):335–342
Reh A, Oktem O, Oktay K (2008) Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril 90(5):1635–1639
Swain SM et al (2009) Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 113(2):315–320
Levine MN et al (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16(8):2651–2658
Venturini M et al (2005) Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 97(23):1724–1733
Berliere M et al (2008) Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer 8:56
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Ruddy, K.J., Partridge, A.H. (2012). The Unique Reproductive Concerns of Young Women with Breast Cancer. In: Quinn, G., Vadaparampil, S. (eds) Reproductive Health and Cancer in Adolescents and Young Adults. Advances in Experimental Medicine and Biology, vol 732. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-2492-1_6
Download citation
DOI: https://doi.org/10.1007/978-94-007-2492-1_6
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-2491-4
Online ISBN: 978-94-007-2492-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)